Actio Biosciences (San Diego, US) is developing a portfolio of drugs to modulate the activity of proteins responsible for rare diseases with the potential to translate these findings into common diseases – actiobio.com
Location: United States, California, San Diego
Investors 1
| Date | Name | Website |
| - | Droia Onco... | droiaventu... |
Persons 3
| Date | First Name | Last Name | Title | Location | |||
| - | David B. | Goldstein | Chief Exec... | linkedin.c... | - | d*********... | - |
| - | David | Breckenrid... | Chief Busi... | linkedin.c... | - | D*********... | - |
| - | Sunil | Sahdeo | Senior Dir... | linkedin.c... | - | s*********... | - |
Mentions in press and media 5
| Date | Title | Description |
| 11.08.2026 | Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio | Jazz Pharmaceuticals will acquire Actio Biosciences, Inc. for $820 million. Deal centers around Actio’s lead drug for KCNT+ epilepsy, ABS-1230. The deal expands Jazz’s rare epilepsy portfolio, with ABS-1230 recently accepted into an FDA pro... |
| 13.09.2023 | Actio Biosciences Announces $55 Million Series A Financing to Advance Precision Medicine Approach for Rare and Common Diseases | - |
| 12.09.2023 | Actio Biosciences closes $55M to new therapeutics for rare and common diseases | - |
| - | 9 top West Coast biotechs that VCs say are poised to take off in the next year | Tayfun Coskun/Anadolu Agency/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Insider asked 12 venture capitalists which biotech startups would take off in the next 12 months.... |
| - | Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs | Tyler Le/Insider This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Insider asked 12 venture capitalists which biotech startups would take off in the next 12 months. Here are the 23 companie... |